Amiloride

Generic Name: Amiloride

Brand Names: Midamor

Drug Type: Small Molecule

Chemical Formula: C_₆H_₈ClN_₇O

CAS Number: 2609-46-3

Unique Ingredient Identifier: 7DZO8EB0Z3

Background: A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)

Indication: For use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.

Associated Conditions: Ascites, Calcium Nephrolithiasis, Congestive Heart Failure (CHF), Hypertension, Hypokalemia, Metabolic Alkalosis, Polyuria

Clinical Trials

Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease

Phase 2

Completed

Conditions: Chronic Kidney Disease
Albuminuria

Interventions: Drug: Spironolactone
Drug: Amiloride

First Posted Date: 2015-07-14

Last Posted Date: 2022-12-21

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 21

Registration Number: NCT02497300

Locations: 🇺🇸
Hypertension Research Clinic at UAB, Birmingham, Alabama, United States

Comparison of Single and Combination Diuretics in Low-Renin Hypertension

Phase 4

Conditions: Hypertension

Interventions: Drug: Hydrochlorthiazide
Drug: Amiloride
Drug: Hydrochlorthiazide and Amiloride

First Posted Date: 2015-01-30

Last Posted Date: 2015-07-03

Lead Sponsor: University of Cambridge

Target Recruit Count: 423

Registration Number: NCT02351973

Locations: 🇬🇧
Clinical Pharmacology Unit, Box 110, Level 3 ACCI, Addenbrookes Hospital, Cambridge, United Kingdom

Amiloride for Resistant Hypertension

Phase 4

Completed

Conditions: Hypertension
Type 2 Diabetes Mellitus
Microalbuminuria

Interventions: Drug: Amiloride

First Posted Date: 2014-04-24

Last Posted Date: 2014-04-24

Lead Sponsor: Ib Abildgaard Jacobsen

Target Recruit Count: 80

Registration Number: NCT02122731

Locations: 🇩🇰
Odense University Hospital, Department of Endocrinology, Odense, Denmark
🇩🇰
Sygehus Lillebaelt., Fredericia, Denmark
🇩🇰
Sydvestjysk Hospital, Esbjerg, Esbjerg, Denmark

and more 1 locations

Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease

Not Applicable

Conditions: Hypertension
Diabetic Nephropathies

Interventions: Dietary Supplement: Standardized salt diet
Drug: Amiloride

First Posted Date: 2013-08-07

Last Posted Date: 2013-10-16

Lead Sponsor: University of Southern Denmark

Target Recruit Count: 80

Registration Number: NCT01918488

Locations: 🇩🇰
Cardiovascular and Renal Research, Odense, Denmark

MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial

Phase 2

Completed

Conditions: Secondary Progressive Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Riluzole
Drug: Amiloride
Drug: Fluoxetine

First Posted Date: 2013-07-29

Last Posted Date: 2020-03-26

Lead Sponsor: University College, London

Target Recruit Count: 445

Registration Number: NCT01910259

Locations: 🇬🇧
Gartnavel Royal Hospital, 1055 Great Western Road, Glasgow, United Kingdom
🇬🇧
The Walton Centre, Liverpool, United Kingdom
🇬🇧
Derriford Hospital, Plymouth, United Kingdom

and more 10 locations